Apolipoprotein A-V modulates insulin secretion in pancreatic β-cells through its interaction with midkine

Cellular Physiology and Biochemistry

Volumn 24, Issue 5-6, 2009, Pages 451-460

  Helleboid Chapman, Audrey ^a,d   Nowak, Maxime ^a   Helleboid, Stéphane ^b   Moitrot, Emmanuelle ^a   Rommens, Corinne ^a   Dehondt, Hélène ^a   Héliot, Laurent ^c   Drobecq, Hervé ^c   Fruchart Najib, Jamila ^a   Fruchart, Jean Charles ^a  

^a UNIV LILLE   (France)

^b Genfit SA   (France)

^c INSTITUT DE BIOLOGIE DE LILLE   (France)

^d INSERM   (France)

Author keywords

Apolipoprotein A V; Insulin secretion; Midkine; Pancreatic cells

Indexed keywords

APOLIPOPROTEIN A5; INSULIN; MIDKINE; SMALL INTERFERING RNA;

ANIMAL CELL; ARTICLE; CELL MEMBRANE; CELLULAR DISTRIBUTION; CONFOCAL MICROSCOPY; CYTOSOL; INSULIN RELEASE; NONHUMAN; PANCREAS ISLET BETA CELL; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN LOCALIZATION; PROTEIN PROTEIN INTERACTION; RAT;

MUS; RATTUS;

EID: 70450252196     PISSN: 10158987     EISSN: None     Source Type: Journal    
DOI: 10.1159/000257484     Document Type: Article

References (50)

1. Haffner SM, Lehto S, Ronnemaa T, Pyorala K, Laakso M: Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 1998;339:229-234.
2. Wilson PW: Diabetes mellitus and coronary heart disease. Am J Kidney Dis 1998;32:S89-100.
3. Boden G, Shulman GI: Free fatty acids in obesity and type 2 diabetes: defining their role in the development of insulin resistance and beta-cell dysfunction. Eur J Clin Invest 2002;32 Suppl 3:14-23.
4. Breslow JL: Apolipoprotein genetic variation and human disease. Physiol Rev 1988;68:85-132.
5. Zannis VI, Breslow JL: Genetic mutations affecting human lipoprotein metabolism. Adv Hum Genet 1985;14:125-215, 383-1126.
6. Pennacchio LA, Olivier M, Hubacek JA, Cohen JC, Cox DR, Fruchart JC, Krauss RM, Rubin EM: An apolipoprotein influencing triglycerides in humans and mice revealed by comparative sequencing. Science 2001;294:169-173.
7. van der Vliet HN, Sammels MG, Leegwater AC, Levels JH, Reitsma PH, Boers W, Chamuleau RA: Apolipoprotein A-V: a novel apolipoprotein associated with an early phase of liver regeneration. J Biol Chem 2001;276:44512-44520.
8. van der Vliet HN, Schaap FG, Levels JH, Ottenhoff R, Looije N, Wesseling JG, Groen AK, Chamuleau RA: Adenoviral overexpression of apolipoprotein A-V reduces serum levels of triglycerides and cholesterol in mice. Biochem Biophys Res Commun 2002;295:1156-1159.
9. Jakel H, Nowak M, Helleboid-Chapman A, Fruchart-Najib J, Fruchart JC: Is apolipoprotein A5 a novel regulator of triglyceride-rich lipoproteins? Ann Med 2006;38:2-10.
10. Pennacchio LA, Olivier M, Hubacek JA, Krauss RM, Rubin EM, Cohen JC: Two independent apolipoprotein A5 haplotypes influence human plasma trig-lyceride levels. Hum Mol Genet 2002;11:3031-3038.
11. Ribalta J, Figuera L, Fernandez-Ballart J, Vilella E, Castro Cabezas M, Masana L, Joven J: Newly identified apolipoprotein AV gene predisposes to high plasma triglycerides in familial combined hyperlipidemia. Clin Chem 2002;48:1597-1600.
12. Hubacek JA, Skodova Z, Adamkova V, Lanska V, Poledne R: The influence of APOAV polymorphisms (T-1131C and S19W) on plasma triglyceride levels and risk of myocardial infarction. Clin Genet 2004;65:126-130.
13. Lai CQ, Demissie S, Cupples LA, Zhu Y, Adiconis X, Parnell LD, Corella D, Ordovas JM: Influence of the APOA5 locus on plasma triglyceride, lipoprotein subclasses, and CVD risk in the Framingham Heart Study. J Lipid Res 2004;45:2096-2105.
14. Fruchart-Najib J, Bauge E, Niculescu LS, Pham T, Thomas B, Rommens C, Majd Z, Brewer B, Pennacchio LA, Fruchart JC: Mechanism of triglyceride lowering in mice expressing human apolipoprotein A5. Biochem Biophys Res Commun 2004;319:397-404.
15. Merkel M, Loeffler B, Kluger M, Fabig N, Geppert G, Pennacchio LA, Laatsch A, Heeren J: Apolipoprotein AV accelerates plasma hydrolysis of triglyceride-rich lipoproteins by interaction with proteoglycan-bound lipoprotein lipase. J Biol Chem 2005;280:21553-21560.
16. Oliva C P, Pisciotta L, Li Volti G, Sambataro MP, Cantafora A, Bellocchio A, Catapano A, Tarugi P, Bertolini S, Calandra S: Inherited apolipoprotein A-V deficiency in severe hypertriglyceridemia. Arterioscler Thromb Vasc Biol 2005;25:411-417.
17. Schaap FG, Rensen PC, Voshol PJ, Vrins C, van der Vliet HN, Chamuleau RA, Havekes LM, Groen AK, van Dijk KW: ApoAV reduces plasma triglycerides by inhibiting very low density lipoprotein-triglyceride (VLDL-TG) production and stimulating lipoprotein lipase-mediated VLDL-TG hydrolysis. J Biol Chem 2004;279:27941-27947.
18. Baroukh N, Bauge E, Akiyama J, Chang J, Afzal V, Fruchart JC, Rubin EM, Fruchart-Najib J, Pennacchio LA: Analysis of apolipoprotein A5, c3, and plasma triglyceride concentrations in genetically engineered mice. Arterioscler Thromb Vasc Biol 2004;24:1297-1302.
19. Nowak M, Helleboid-Chapman A, Jakel H, Martin G, Duran-Sandoval D, Staels B, Rubin EM, Pennacchio LA, Taskinen MR, Fruchart-Najib J, Fruchart JC: Insulin-Mediated Down-Regulation of Apolipoprotein A5 Gene Expression through the Phosphatidylinositol 3-Kinase Pathway: Role of Upstream Stimu latory Factor. Mol Cell Biol 2005;25:1537-1548.
20. Prieur X, Huby T, Coste H, Schaap FG, Chapman MJ, Rodriguez JC: Thyroid hormone regulatesthe hypotriglyceridemic gene APOA5. J Biol Chem 2005;280:27533-27543.
21. Genoux A, Dehondt H, Helleboid-Chapman A, Duhem C, Hum DW, Martin G, Pennacchio LA, Staels B, Fruchart-Najib J, Fruchart JC: Transcriptional regulation of apolipoprotein A5 gene expression by the nuclear receptor RORalpha. Arterioscler Thromb Vasc Biol 2005;25:1186-1192.
22. Jakel H, Nowak M, Moitrot E, Dehondt H, Hum DW, Pennacchio LA, Fruchart-Najib J, Fruchart JC: The liver X receptor ligand T0901317 down-regulates APOA5 gene expression through activation of SREBP-1c. J Biol Chem 2004;279:45462-45469.
23. Lind U, Nilsson T, McPheat J, Stromstedt PE, Bamberg K, Balendran C, Kang D: Identification of the human ApoAV gene as a novel RORalpha target gene. Biochem Biophys Res Commun 2005;330:233-241.
24. Prieur X, Coste H, Rodriguez JC: The human apolipoprotein AV gene is regulated by peroxisome proliferator-acti-vated receptor-alpha and contains a novel farnesoid X-activated receptor response element. J Biol Chem 2003;278:25468-25480.
25. Vu-Dac N, Gervois P, Jakel H, Nowak M, Bauge E, Dehondt H, Staels B, Pennacchio LA, Rubin EM, Fruchart-Najib J, Fruchart JC: Apolipoprotein A5, a Crucial Determinant of Plasma Trig-lyceride Levels, Is Highly Responsive to Peroxisome Proliferator-activated Receptor alpha Activators. J Biol Chem 2003;278:17982-17985.
26. Kadomatsu K, Tomomura M, Muramatsu T: cDNA cloning and sequencing of a new gene intensely expressed in early differentiation stages of embryonal carcinoma cells and in mid-gestation period of mouse embryogenesis. Biochem Biophys Res Commun 1988;151:1312-1318.
27. Tomomura M, Kadomatsu K, Nakamoto M, Muramatsu H, Kondoh H, Imagawa K, Muramatsu T: A retinoic acid responsive gene, MK, produces a secreted protein with heparin binding activity. Biochem Biophys Res Commun 1990;171:603-609.
28. Muramatsu H, Zou K, Sakaguchi N, Ikematsu S, Sakuma S, Muramatsu T: LDL receptor-related protein as a component of the midkine receptor. Biochem Biophys Res Commun 2000;270:936-941.
29. Mitsiadis TA, Salmivirta M, Muramatsu T, Muramatsu H, Rauvala H, Lehtonen E, Jalkanen M, Thesleff I: Expression of the heparin-binding cytokines, midkine (MK) and HB-GAM (pleiotrophin) is associated with epithelial-mesenchymal interactions during fetal development and organogenesis.Development 1995;121:37-51.
30. Nakanishi T, Kadomatsu K, Okamoto T, Ichihara-Tanaka K, Kojima T, Saito H, Tomoda Y, Muramatsu T: Expression of syndecan-1 and-3 during embryogenesis of the central nervous system in relation to binding with midkine. J Biochem (Tokyo) 1997;121:197-205.
31. Maeda N, Ichihara-Tanaka K, Kimura T, Kadomatsu K, Muramatsu T, Noda M: A receptor-like protein-tyrosine phos-phatase PTPzeta/RPTPbeta binds a heparin-binding growth factor midkine. Involvement of arginine 78 of midkine in the high affinity binding to PTPzeta. J Biol Chem 1999;274:12474-12479.
32. Stoica GE, Kuo A, Powers C, Bowden ET, Sale EB, Riegel AT, Wellstein A: Midkine binds to anaplastic lymphoma kinase (ALK) and acts as a growth factor for different cell types. J Biol Chem 2002;277:35990-35998.
33. Beecken WD, Kramer W, Jonas D: New molecular mediators in tumor angiogen-esis. J Cell Mol Med 2000;4:262-269.
34. Zhang N, Deuel TF: Pleiotrophin and midkine, a family of mitogenic and ang-iogenic heparin-binding growth and differentiation factors. Curr Opin Hematol 1999;6:44-50.
35. Tsutsui J, Kadomatsu K, Matsubara S, Nakagawara A, Hamanoue M, Takao S, Shimazu H, Ohi Y, Muramatsu T: A new family of heparin-binding growth/differentiation factors: increased midkine expression in Wilms? tumor and other human carcinomas. Cancer Res 1993;53:1281-1285.
36. Kojima S, Muramatsu H, Amanuma H, Muramatsu T: Midkine enhances fibri-nolytic activity of bovine endothelial cells. J Biol Chem 1995;270:9590-9596.
37. Takada T, Kinkori T, Muramatsu H, Hayakawa A, Torii S, Muramatsu T: Midkine, a retinoic acid-inducible heparin-binding cytokine, is a novel regulator of intracellular calcium in human neutrophils. Biochem Biophys Res Commun 1997;241:756-761.
38. Owada K, Sanjo N, Kobayashi T, Mizusawa H, Muramatsu H, Muramatsu T, Michikawa M: Midkine inhibits caspase-dependent apoptosis via the activation of mitogen-activated protein kinase and phosphatidylinositol 3-kinase in cultured neurons. J Neurochem 1999;73:2084-2092.
39. Kojima S, Inui T, Muramatsu H, Suzuki Y, Kadomatsu K, Yoshizawa M, Hirose S, Kimura T, Sakakibara S, Muramatsu T: Dimerization of midkine by tissue transglutaminase and its functional implication. J Biol Chem 1997;272:9410-9416.
40. Salama RH, Muramatsu H, Zou K, Inui T, Kimura T, Muramatsu T: Midkine binds to 37-kDa laminin binding protein precursor, leading to nuclear transport of the complex. Exp Cell Res 2001;270:13-20.
41. Helleboid-Chapman A, Helleboid S, Jakel H, Timmerman C, Sergheraert C, Pattou F, Fruchart-Najib J, Fruchart JC: Glucose regulates LXRalpha subcellular localization and function in rat pancreatic beta-cells. Cell Res 2006;16:661-670.
42. Coutte L, Antoine R, Drobecq H, Locht C, Jacob-Dubuisson F: Subtilisin-like autotransporter serves as maturation protease in a bacterial secretion pathway. Embo J 2001;20:5040-5048.
43. O'Brien PJ, Alborn WE, Sloan JH, Ulmer M, Boodhoo A, Knierman MD, Schultze AE, Konrad RJ: The novel apolipoprotein A5 is present in human serum, is associated with VLDL, HDL, and chylomicrons, and circulates at very low concentrations compared with other apolipoproteins. Clin Chem 2005;51:351-359.
44. Baum L, Tomlinson B, Thomas G: APOA5-1131TC polymorphism is associated with triglyceride levels in Chinese men. Clin Genet 2003;63:377-379.
45. Endo K, Yanagi H, Araki J, Hirano C, Yamakawa-Kobayashi K, Tomura S: Association found between the promoter region polymorphism in the apolipoprotein A-V gene and the serum triglyceride level in Japanese schoolchildren. Hum Genet 2002;111:570-572.
46. Martin S, Nicaud V, Humphries SE, Talmud PJ: Contribution of APOA5 gene variants to plasma triglyceride determination and to the response to both fat and glucose tolerance challenges. Biochim Biophys Acta 2003;1637:217-225.
47. Talmud PJ, Hawe E, Martin S, Olivier M, Miller GJ, Rubin EM, Pennacchio LA, Humphries SE: Relative contribution of variation within the APOC3/A4/A5 gene cluster in determining plasma triglycerides. Hum Mol Genet 2002;11:3039-3046.
48. Shibata Y, Muramatsu T, Hirai M, Inui T, Kimura T, Saito H, McCormick LM, Bu G, Kadomatsu K: Nuclear targeting by the growth factor midkine. Mol Cell Biol 2002;22:6788-6796.
49. Lookene A, Beckstead JA, Nilsson S, Olivecrona G, Ryan RO: Apolipoprotein A-V-heparin interactions: implications for plasma lipoprotein metabolism. J Biol Chem 2005;280:25383-25387.
50. Chiu KC, Chiu YF, Boyadjian AA, Fernando S, Kwan C, Chuang LM: Impact of apolipoprotein A5 polymorphisms on insulin sensitivity and beta-cell function. Pancreas 2005;30:328-332